FDA clears Baxter’s Novum IQ LVP and dose IQ safety software

Baxter International announced U.S. Food and Drug Administration FDA 510 k clearance of its Novum IQ large volume infusion pump LVP with Dose IQ Safety Software. Adding LVP modality to the Novum IQ Infusion Platform – which includes Baxter’s syringe infusion pump with Dose IQ Safety Software, powered by the IQ Enterprise Connectivity Suite – enables clinicians to utilize a single, integrated system across a variety of patient care settings. Offering the Novum IQ LVP in the U.S. demonstrates Baxter’s commitment to continued innovation in advancing infusion therapy. Heather Knight, executive vice president and group president, Medical Products and Therapies at Baxter, highlighted the customer-centric approach of the Novum IQ platform, emphasizing its role in helping to enhance care delivery. “Our goal, always, is to bring increased efficiency, safety and opportunity for informed decision-making to our customers, clinicians and the patients they serve,” Knight commented. “The Novum IQ platform represents a meaningful shift in how connected and intelligent infusion therapy can impact the way clinicians provide care. Offering Novum IQ large volume and syringe infusion pumps unlocks the potential of advanced, intuitive technologies that customers seek to meet their needs.”